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Background: Classic galactosemia (OMIM #230400) is an autosomal recessive metabolic disorder caused by a
deficiency of the galactose-1-phosphate uridyltransferase (GALT, EC2.7.7.12) protein due to mutations in the GALT
gene. The aim of this study was to provide a comprehensive and updated mutation spectrum of GALT in a Korean
population.
Methods: Thirteen unrelated patients screened positive for galactosemia in a newborn screening program were
included in this study. They showed a reduced GALT enzyme activity in red blood cells. Direct sequencing of the
GALT gene and in silico analyses were done to evaluate the impact of novel variations upon GALT enzyme activity.
We also reviewed previous reports for GALT mutations in Koreans.
Results: We identified six novel likely pathogenic variations including three missense (p.Ala101Asp, p.Tyr165His, and
p.Pro257Thr), one small deletion/insertion [c.826_827delinsAA (p.Ala276Asn)], one frameshift (p.Asn96Serfs*5), and
one splicing (c.378-1G > C) likely pathogenic variations. The most frequent variation was the Duarte variant
(c.940A > G, 35.3%), followed by c.507G > C (p.Gln169His, 9.6%), among 34 Korean patients. Other mutations were
widely scattered. None of the eight common mutations used for targeted mutation analysis in Western countries
including p.Gln188Arg, p.Ser135Leu, p.Lys285Asn, p.Leu195Pro, p.Tyr209Cys, p.Phe171Ser, c.253-2A > G, and a 5 kb
deletion, had been found in Koreans until this study.
Conclusions: Considering the mutation spectrum in Koreans, direct sequence analysis of entire GALT exons is
recommended for accurate diagnosis. The mutations responsible for GALT deficiency in the Korean population
were clearly different from those of other populations.
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Classical galactosemia (OMIM #230400) is an autosomal
recessive inborn error of metabolism caused by a defi-
ciency of the galactose-1-phosphate uridyltransferase
(GALT, EC2.7.7.12) protein, which is encoded by the GALT
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Galactosemia is a potentially fatal disease that mani-
fests within the first week of life with poor feeding,
jaundice, vomiting, liver dysfunction, increased bleed-
ing tendency, and septicemia, leading to death if un-
treated [2]. It is well known that early detection of
galactosemia and management with dietary restriction
of galactose can prevent infants from a deteriorating state
and leads to rapid clinical improvement. Many patients
develop long-term complications, with a broad range of
clinical symptoms such as cataracts, speech defects, poor
growth, poor intellectual function, neurologic deficits,
and premature ovarian insufficiency [3]. Many countriesd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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to detect and manage the disease earlier [4]. A wide range
of galactosemia frequency was estimated in Western
countries (1:14,000 to 1:80,000) [4,5] and much lower
frequency reported in Asian populations [6,7]. To date,
more than 230 mutations responsible for galactosemia
have been identified and updated in the GALT gene data-
bases [8,9]. Eight common GALT mutations for targeted
mutation analysis have been introduced in Western
countries, which include p.Gln188Arg, p.Ser135Leu,
p.Lys285Asn, p.Leu195Pro, p.Tyr209Cys, p.Phe171Ser,
c.253-2A > G, and a 5 kb deletion [10-12]. However,
none of these mutations have been reported in Asian
populations. Since there is a wide range of mutations
among different ethnic background, genetic analysis is
needed to understand the mutation spectrum of GALT in
the Korean population. In Korea, a nationwide newborn
screening program for galactosemia, first introduced in
1991, is now performed on more than 90% of Korean
newborns [13]. Only 21 Korean patients with GALT-
deficient galactosemia have been reported, which suggests
a low prevalence [14,15]. The aim of this study was to
characterize and update the spectrum of GALT gene varia-
tions in Korean patients using direct sequence analysis
and to produce a comprehensive literature review of
GALT mutations in the Korean population.
Methods
Patients
Thirteen unrelated Korean children with abnormal new-
born screening results for galactosemia and reduced
GALT activities between April 2010 and April 2013
from two institutions (Samsung Medical Center and
Soonchunhyang University Hospital) were included in
this study. Ninety-six healthy subjects were also included
as controls in order to exclude common polymorphisms
for six novel variations. Additionally, a comprehensive
review of the literature with previously reported GALT
mutations in Koreans was conducted. This research was
approved by the Samsung Medical Center Institutional
Review Board and written informed consent was ob-
tained from all subjects and/or their parents whenever
possible.
GALT enzyme activity in red blood cells
GALT enzyme activity in red blood cells was mea-
sured by an established radiometric assay [16] and
was expressed in μmol/hour (hr)/g hemoglobin (Hb). The
reference range of GALT enzyme activity is from 20 to
35 μmol/hr/g Hb.
DNA amplification and direct sequence analysis
Human genomic DNA was prepared from frozen white
blood cells using a Wizard genomic DNA purificationkit (Promega, Madison, WI, USA) according to the man-
ufacturer’s recommendations. All 11 exons and the
flanking regions of the GALT gene were amplified by
polymerase chain reaction (PCR) using primers designed
by the authors (sequences available upon request) and a
thermal cycler (Model 970; Applied Biosystems, Foster
City, CA, USA). Direct sequencing of the DNA was
performed using the ABI Prism 3100 Genetic Analyzer
(Applied Biosystems, Foster City, CA, USA) with the
BigDye Terminator Cycle Sequencing-Ready Reaction
Kit (Applied Biosystems Foster City, CA, USA). Nucleo-
tides are numbered from the first adenine of the ATG
translation initiation codon in the GALT cDNA Reference
Sequence NM_000155.2.
Pathologic predictions of novel substitution variants
We performed in silico analyses to identify the muta-
tional status of a novel exonic variation using two differ-
ent servers. PolyPhen-2 prediction was used to identify
the functional effect of human non-synonymous single
nucleotide polymorphisms (http://genetics.bwh.harvard.
edu/pph2/) and the second prediction program was SIFT
(Sorting Intolerant From Tolerant, http://sift.jcvi.org/).
“Damaging change” in PolyPhen-2 and “not tolerated” in
SIFT both mean that the missense variation may be a mu-
tation rather than a polymorphism. We also used the
Human Splicing Finder (http://www.umd.be/HSF/) to pre-
dict any difference in splicing between the novel mutants
and their respective wild-type reference sequences to esti-
mate the mutation status of novel substitution variants. If
in silico analyses predicted the novel variants to be likely
pathogenic, then the novel variations are defined as likely
pathogenic variations rather than detrimental mutations
because expression studies were not performed.
Genetic analysis of normal individuals
The tests targeted the six novel sequence variations re-
vealed in this study and were conducted on 192 alleles
from 96 healthy adult individuals without any clinical
symptoms of galactosemia. All genetic analyses were done
using direct sequence analysis, as explained above.
Statistical tests
We applied the Kruskal-Wallis test with post-hoc ana-
lysis for comparison of patients with different variant
alleles for the GALT gene including the Duarte variant
using the MedCalc program for Windows, version 12.2.1
(MedCalc Software, Mariakerke, Belgium). A p value of
less than 0.05 was considered significant.
Results
Demographics of GALT-deficient galactosemia
During the 3-year study period, 13 unrelated patients
with GALT deficiency (six males and seven females)
Choi et al. BMC Medical Genetics 2014, 15:94 Page 3 of 8
http://www.biomedcentral.com/1471-2350/15/94were included in this study. The median age at molecu-
lar diagnosis in the 13 Korean galactosemia subjects was
2.9 months (range, 1 month – 23 months). All but one had
no significant clinical symptoms or signs of galactosemia.
Only one patient had jaundice and cataracts whose age at
molecular diagnosis was 23 months. All of the children
with abnormal newborn screening results for galactosemia
and reduced GALT activities started treatment with dietary
galactose restriction.
Sequence variations in the GALT gene in 13 Korean
galactosemia patients
All 13 patients with reduced GALT activity had various
sequence variations in the GALT gene. A total of 20 vari-
ant alleles (76.9%) were identified, corresponding to 12
different variations. We identified seven alleles with five
known pathogenic mutant alleles, seven alleles with six
novel likely pathogenic variant alleles, and six alleles with
the Duarte variant allele. The five known mutations in-
cluded four missense mutations [c.346C >A (p.Leu116Ile),
c.602G >A (p.Arg201His), c.998G >A (p.Arg333Gln), and
c.1087G >A (p.Glu363Lys)] and one intronic mutation
(c.821-7A > G), which causes a splicing aberration
(exon 9 deletion). The six novel likely pathogenic vari-
ations consisted of three missense variations [c.302C >A
(p.Ala101Asp), c.493 T > C (p.Tyr165His), and c.769C >A
(p.Pro257Thr)], one small deletion/insertion [c.826_
827delinsAA (p.Ala276Asn)], one frameshift [c.286_299del
GACAACGACTTCCC (p.Asp96Serfs*5)], and one splicing
(c.378-1G >C) variation. Five patients had the Duarte vari-
ant allele (c.940A >G) and one was homozygous. Individual
characteristics of the GALT genotype in the 13 patients used
in this study are summarized in Table 1.
Structural and functional effects of novel variations
In silico analyses for four novel nucleotide substitu-
tions and one novel in frame deletion/insertion muta-
tion were predicted using PolyPhen-2 and SIFT. The
possible mis-splicing effect of exonic or intronic vari-
ations predicted using Human Splice Finder is sum-
marized in Table 2. Three novel variations of c.302C >A
(p.Ala101Asp), c.796C > A (p.Pro257Thr), and c.826_
827delinsAA (p.Ala276Asn) were predicted as muta-
tions by PolyPhen-2 and SIFT. The novel variation of
c.493 T > C (p.Tyr165His) was predicted to be a poly-
morphism by both PolyPhen-2 and SIFT. However, it
was predicted to activate a cryptic splice site of an en-
hancer motif causing aberrant splicing according to the
Human Splice Finder matrix. The c.493 T > C variation
was observed in one patient who was a compound het-
erozygote for the previously reported pathogenic muta-
tion, c.998G > A (p.Arg333Gln), and the patient had
6.3 μmol/h/g Hb of GALT activity, suggesting that this
variation might be pathogenic.The possible mis-splicing effect of silent exonic or
intronic variations located outside of the canonical spli-
cing signals, AG or GT, also revealed that c.302C > A
(p.Ala101Asp) was predicted to activate a cryptic splice
site of an enhancer motif. This variation was detected in
one patient who was a compound heterozygote for the
Duarte variant (D/G galactosemia) with 6.2 μmol/h/g Hb
of GALT activity, which supports the hypothesis that this
variation may be pathogenic rather than benign. The
intronic variation of c.378-1G > C was predicted to im-
pact the splice site through both activation of a cryptic
splice site of an enhancer motif and disruption of a nat-
ural silencer motif. This variation was identified in one
patient heterozygous for the other novel likely patho-
genic variant allele [c.286_299delGACAACGACTTCCC
(p. Asp96Serfs*5)] with GALT enzymatic activity below
the quantitation limit of 0.1 μmol/h/g Hb. Also, another
patient with 7.3 μmol/h/g Hb of GALT activity, was com-
pound heterozygous for c.286_299delGACAACGACTT
CCC and c.821-7A > G. A known mutant allele of c.821-
7A > G was reported to cause an exon 9 deletion. In
addition, six novel variations were absent in the 192 al-
leles from healthy individuals.
An intronic variation of c.82 + 20_82 + 60del was ob-
served in one patient who was compound heterozygous
for two other novel likely pathogenic variant alleles,
c.286_299delGACAACGACTTCCC and c.378-1G > C,
and had no GALT enzyme activity (<0.1 μmol/h/g Hb),
which suggests that this variation is a polymorphism with-
out significant enzymatic effect.
Mutation spectrum of the GALT gene in Korean patients
Table 3 summarizes all the variations in the GALT gene,
including previously published data in Korea and this
study. Thirty-four Korean patients with GALT deficiency
galactosemia were recruited and a total of 51 variant al-
leles were identified (75.0%, 51/68 alleles). The most fre-
quent nucleotide substitution was the Duarte variant
(c.940A > G, n = 18, 35.3%), followed by c.507G > C
(p.Gln169His, n = 5, 9.8%). Among the 34 Korean pa-
tients, eight (23.5%) had classic galactosemia with two
pathogenic variant alleles, eight (23.5%) were compound
heterozygous for a Duarte variant and a pathogenic vari-
ant allele, nine (26.5%) were heterozygous for only one
pathogenic variant allele, eight (23.5%) were heterozy-
gous for one Duarte variant allele, and one (2.9%) was
homozygous for the Duarte variant allele. The GALT
mutational spectrum is comprised of 18 distinct vari-
ations that are widely scattered. Most of the putative
disease-causing variations were missense variations (n = 11,
61.1%), with the other variants being small deletion/inser-
tions (n = 2, 11.1%), exonic or intronic variations that could
affect splicing (n = 4, 22.2%) and silent exonic variations
(n = 1, 5.6%).
Table 1 Individual characteristics of the GALT genotype in 13 Korean patients with decreased GALT enzyme activity
Case no. Age (month) Sex Location Nucleotide change* Amino acid change GALT activity†
(μmol/h/g Hb)
Category‡
1 24.5 M Exon 3 c.286_299delGACAACGACTTCCC p.Asp96Serfs*5 < 0.1 G/G
IVS 4 c.378-1G > C p.?
2 1.8 F Exon 3 c.286_299delGACAACGACTTCCC p.Asp96Serfs*5 7.3 G/G
IVS 8 c.821-7A > G Exon 9 deletion
3 2.3 F Exon 5 c.493 T > C p.Tyr165His 6.3 G/G
Exon 10 c.998G > A p.Arg333Gln
4 1.7 M Exon 10 c.998G > A p.Arg333Gln 1.8 G/G
Exon 10 c.998G > A p.Arg333Gln
5 1.1 F Exon 3 c.302C > A p.Ala101Asp 6.2 G/D
Exon 10 c.940A > G p.Asn314Asp§
6 2.9 M Exon 9 c.826_827delinsAA p.Ala276Asn 5.9 G/D
Exon 10 c.940A > G p.Asn314Asp§
7 3.1 M Exon 4 c.346C > A p.Leu116Ile 15.6 G/N
8 2.2 F Exon 7 c.602G > A p.Arg201His 14.5 G/N
9 3.1 M Exon 8 c.769C > A p.Pro257Thr 11.6 G/N
10 2.9 F Exon 11 c.1087G > A p.Glu363Lys 16.4 G/N
11 3.0 F Exon 10 c.940A > G p.Asn314Asp§ 12.5 D/D
12 3.5 F Exon 10 c.940A > G p.Asn314Asp§ 12.6 D/N
13 5.2 M Exon 10 c.940A > G p.Asn314Asp§ 16.1 D/N
GALT galactose-1-phosphate uridyltransferase.
*Nucleotide numbering was based on the GALT cDNA sequence (RefSeq NM_000155.2) with nucleotide +1 being the A of the first ATG translation
initiation codon.
†The reference range of GALT enzyme activity was 20–35 μmol/h/g Hb for normal healthy individuals and the limit of quantitation was 0.1 μmol/h/g Hb.
‡D, Duarte variant; G, allele for galactosemia including novel likely pathogenic variant; N, normal allele.
§Duarte variant.
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summarized in Figure 1. The GALT enzyme activities of
patients varied according to genotype with overlapping
distributions: mean 3.9 μmol/h/g Hb for classic galacto-









Exon 3 c.302C > A p.Ala101Asp Probably damaging 0.998
Exon 5 c.493 T > C p.Tyr165His Benign 0.440
Exon 8 c.769C > A p.Pro257Thr Probably damaging 0.998
Exon 9 c.826_827delinsAA p.Ala276Asn Probably damaging 0.995
IVS4 c.378-1G > C NA NA NA
NA not applicable or not analyzed.
*The reference range of GALT enzyme activity was 20–35 μmol/h/g Hb for normal hfor compound heterozygotes of Duarte and classic variants
(range, 5.9–6.2), 12.5 μmol/h/g Hb for Duarte homozy-
gotes, mean 14.5 μmol/h/g Hb for carriers of classic mu-
tant alleles (range, 11.6–16.4), and mean 14.4 μmol/h/g Hb




SIFT Splicing effect Affected motif
Not tolerated Activation of a cryptic
splice site
Enhancer motif 6.2
Tolerated Activation of a cryptic
splice site
Enhancer motif 6.3
Not tolerated No effect No effect 11.6
Not tolerated No effect No effect 5.9
NA Activation of a cryptic
splice site
Enhancer motif <0.1
Disruption of a natural
motif
Silencer motif
ealthy individuals and the limit of quantitation was 0.1 μmol/h/g Hb.
Table 3 Genetic spectrum and allele frequency of likely pathogenic GALT variations in 34 Korean GALT-deficient
galactosemia patients
Location Nucleotide change Amino acid change Allele number Previously reported in Koreans
Missense mutation
Exon 2 c.92A > G p.His31Arg 1 Ko et al. [14]
Exon 3 c.302C > A p.Ala101Asp 1 This study, novel
Exon 4 c.346C > A p.Leu116Ile 2 Ko et al. [14], this study
Exon 5 c.493 T > C p.Tyr165His 1 This study, novel
Exon 5 c.507G > C p.Gln169His 5 Ko et al. [14], Lee et al. [15]
Exon 6 c.557A > C p.His186Pro 3 Ko et al. [14]
Exon 7 c.602G > A p.Arg201His 2 Ko et al. [14], this study
Exon 8 c.769C > A p.Pro257Thr 1 This study, novel
Exon 10 c.940A > G p.Asn314Asp* 18 Ko et al. [14], this study
Exon 10 c.998G > A p.Arg333Gln 3 This study†
Exon 11 c.1087G > A p.Glu363Lys 2 Lee et al. [15], this study
Small deletion/insertion leading to frameshift
Exon 3 c.286_299delGACAACGACTTCCC p.Asp96Serfs*5 2 This study, novel
Small deletion/insertion (in-frame)
Exon 9 c.826_827delinsAA p.Ala276Asn 1 This study, novel
Silent exonic variation
Exon 10 c.999G > A p.Arg333= 1 Ko et al. [14]
Splicing aberration
IVS 2 c.252 + 1G > A Exon 2 deletion 3 Lee et al. [15]
IVS 6 c.565-2A > G Exon 7 deletion 1 Ko et al. [14]
IVS 8 c.821-7A > G Exon 9 deletion 3 Ko et al. [14], this study
Predicted to cause splicing aberration
IVS 4 c.378-1G > C p.? 1 This study, novel
Considered as a rare polymorphism
IVS 1 c.82 + 20_82 + 60del p.? 1 This study, novel‡
*Duarte variant.
†Although this variation has not been previously reported in Koreans, it is a known pathogenic mutation identified in the Japanese population and reported by
Hirokawa et al. [6].
‡This variation was found in a patient who was compound heterozygous for c.286_299delGACAACGACTTCCC and c.378-1G > C.
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nificantly different from other groups with different
variant alleles (p < 0.05). The differences of GALT activ-
ities between carriers of classic variant alleles and car-
riers of the Duarte variant allele were not significantly
different (p > 0.05). Because only one patient was homo-
zygous for the Duarte variant allele, it was difficult to
compare GALT activities among different groups with
variant alleles and there were no significant differences
from other groups of patients with variant alleles except
for the group of classic galactosemia patients (p > 0.05).
Discussion
Among 34 Korean patients with GALT mutations in-
cluding likely pathogenic variants, the most common
type of disease-causing mutation was a missense mutation(61.1%) followed by a splicing mutation (22.2%). The most
common mutation except for the Duarte variant was
c.507G >C (p.Gln169His) and it was found in five out of
51 variant alleles (9.8%). Other mutations previously found
in the Korean population were widely scattered in our pa-
tients and no other specific mutations were found to be
prevalent at a significant frequency, which makes targeted
mutation analysis difficult.
Our study also reaffirmed that measurement of GALT
enzyme activity was not enough to predict the genotypes
and to make a decision for treatment in some patients
because of the lack of correlation between genotype and
phenotype [17,18]. For the galactosemia variant, the D/G
phenotype of GALT activity in which at least one muta-
tion is the c.940A > G (p.Asn314Asp) allele with the
enzyme activity between 5% and 50% of normal control
Figure 1 GALT enzyme activities among different categories of GALT biochemical phenotypes in 34 Korean patients. The bars in the
boxes represent the median values, and the areas above and below the bars in the boxes represent the upper and lower quartiles, respectively.
The lines extending below and above the boxes represent the lowest and highest values, respectively, and the circles represent individual data.
P value was calculated by the comparison among five different groups of patients with GALT biochemical phenotypes by the Kruskal-Wallis test
with post-hoc analysis (D, Duarte variant; G, mutant allele for galactosemia including novel likely pathogenic variant; N, normal allele). It is of note
that although there were differences in GALT activity between the G/G and D/G patient groups, the GALT enzyme activities of individual patients
were varied with overlapping distributions.
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cellular damage, cataract, or developmental delays dur-
ing infancy, the need to restrict dietary galactose is
uncertain [19,20]. In our study, there were eight patients
with the D/G GALT biochemical phenotype among 34
GALT-deficient galactosemia patients, and these pa-
tients had an enzyme activity of 5.9–15.8 μmol/h/g Hb
(median 7.0 μmol/h/g Hb), corresponding to 21.5–57.5%
of the mean control value. Although there were differ-
ences in GALT activity between the G/G and D/G patient
groups, the GALT enzyme activities of individual patients
were varied with overlapping distributions. It is reason-
able and important to distinguish D/G galactosemia from
G/G classic galactosemia using a molecular diagnostic
test prior to making any treatment decisions. We report
the first Korean patient with two Duarte variants who
is in the homozygous state of the Duarte variant allele
(D/D). Her GALT activity was 12.5 μmol/h/g Hb cor-
responding to 35.7–62.5% of normal control values (20–
35 μmol/h/g Hb), which is consistent with previously
reported data [21].
The incidence of GALT galactosemia varies, ranging
from 1 in 23,000–40,000 in Europe [17,22] to 1 in 50,000
in the United States [10]. It has been reported that the fre-
quency of GALT galactosemia has decreased in continen-
tal Europe, moving through populations in an eastern
and southern direction [17]. Using haplotype analysisin conjunction with a measure of genetic diversity and
linkage disequilibrium, it was found that p.Gln188Arg
arose in central Europe within the last 20,000 years,
possibly due to population expansion during the re-
colonization of Europe by Homo sapiens in the Mesolithic
Age. p.Lys285Asn is a younger mutation that originated
in Eastern Europe and is probably more geographically
restricted since it arose after all major European popu-
lation expansions [23]. The Duarte variant, c.940A > G
(p.Asn314Asp), was found to be an ancient mutation
that originated before the expansion of Homo sapiens
out of Africa [10,23]. In Asian countries, the incidences
of classic galactosemia is reported to be much lower
than in Western countries, ranging from 1 in 1,000,000
in Japan to 1 in 500,000 in China [6].
In Korea, the nationwide newborn screening for galac-
tosemia was first introduced in 1991. From 1997 to
2005, it was stopped due to budget concerns and cost-
effectiveness of the newborn screening program and
then resumed in 2006 [24]. According to the annual re-
port of the Ministry of Health and Welfare of Korea,
about 80.4% of newborns were screened by the nation-
wide newborn screening program from 1991 to 2007.
After 2006, the incidence of galactosemia has increased
from 1:100,000 in 2006 to around 1:15,000 in 2012, and
prevalence of galactosemia in Korea was calculated to be
between 1:30,000 and 1:35,000 from 2005 to 2012 [13,25].
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lactosemia is not yet known. Although it is very difficult to
evaluate the accurate prevalence of classic galactosemia in
the Korean population, some previous reports have sug-
gested a lower prevalence in Koreans compared to West-
ern countries [13-15,24]. Ko et al. reported only one
classic galactosemia patient in 18 patients with reduced
GALT activities [14], and Lee et al. reported three classic
galactosemia patients during the 11-year study period
[15], which suggested a low prevalence of classic ga-
lactosemia in the Korean population. However, during
the 3-year period in this study, which was relatively
shorter than in previous studies, four classic galactosemia
patients were diagnosed, which suggests that the preva-
lence of classic galactosemia in the Korean population
may be increasing. One cause for the increase in galacto-
semia incidence could be due to a different panel of
populations screened. Another reason attributing to the
higher prevalence observed may be due to different
methods used more recently with respect to old methods.
Lastly, other unknown variables that have been taken into
account to explain the increasing of prevalence. In Korea,
the accreditation and inspection program by the Planned
Population Federation of Korea for the proper quality as-
surance of clinical laboratory performing newborn screen-
ing tests has been settled since 2008 which could also
affect the increasing prevalence of galactosemia [4,25].
Further studies are needed to evaluate the accurate preva-
lence of classic galactosemia combined with comprehen-
sive monitoring program.
To date, more than 230 mutations have been identified
in the GALT gene databases [8,9]. Eight common GALT
mutations for targeted mutation analysis of p.Gln188Arg,
p.Ser135Leu, p.Lys285Asn, p.Leu195Pro, p.Tyr209Cys,
p.Phe171Ser, c.253-2A > G, and a 5 kb deletion have
been introduced as a cost-effective diagnostic strategy in
Western countries [10-12]. Also, other diagnostic methods
such as matrix assisted laser desorption/ionization time-of-
flight mass spectrometry, PCR using an amplification
refractory mutation system, and multiplexed single nu-
cleotide extension techniques have also been introduced
for both population-based screening and diagnosis in pa-
tients [4,18,26-28]. However, none of the above eight
common mutations have been found in the Korean
population as well as another East Asian populations in-
cluding Chinese and Japanese [6,7,14,15,29]. These find-
ings strongly indicate that the Asian GALT mutations are
clearly different from the European mutations because of
the genetic divergence of Homo sapiens [6,17,23]. Al-
though further evaluation is needed to confirm the origin
and the exact effect of the six novel likely pathogenic var-
iations identified in this study, our work suggests that
these variants could be young mutations that may only
be found in those of Asian ethnicity. Taking into accountof all these findings, it is reasonable to suggest that the
mutation databases in the Asian population be separated
or regarded as a distinct category from those of Western
countries for the best diagnostic approach and for devel-
opment and application of therapeutic approaches in
Asian patients with GALT-deficient galactosemia.
It is possible that the difference in the prevalence of
classic galactosemia between countries is due to tech-
nical issues with the population-based newborn screen-
ing programs rather than true population differences [4].
Differences in approach or sensitivity of the methods
used to detect GALT deficiency, or in defined cut-off
levels, may leave some heterozygotes and/or Duarte vari-
ants included in some population estimates but not
others [4]. For example, Africa has an estimated preva-
lence of 1:14,000, which is based on a population-based
screen of cord blood samples for the p.Ser135Leu GALT
mutation and accounts for > 90% of all classic galacto-
semia cases in this population [30]. The increasing detec-
tion rate of galactosemia in the Korean population
should be further evaluated with a focus on the screening
procedures.
Conclusions
In summary, we identified six novel likely pathogenic varia-
tions and expanded the genetic spectrum of GALT varia-
tions in Koreans. The mutations responsible for GALT
deficiency in the Korean population were clearly different
from those of other populations, and common mutations
with high frequency in Western countries are not found in
Koreans. GALT mutations are very widely scattered along
the entire length of the gene, so targeted mutational ana-
lysis for screening or diagnosis is not appropriate.
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